Floatz logo

Posaconazole

Genetic Predisposition

Bochud Pierre-YvesSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Genetic Predisposition cohort.

Asset / SponsorPhaseRating
Cephalexin
University of California, San Francisco
Phase 2CCC
Aln-Pnp
Regeneron Pharmaceuticals
Phase 1CC
Minoxidil
Duke University
Phase 1CC
Fluconazole
Bochud Pierre-Yves
N/AD
BLOOD, WHOLE
University Hospital, Lille
D

Same molecule, other indications

Posaconazole is also rated in:

acute myeloid leukemiaDormant
BBB
Indicative ·
74 / 100
View asset →
fungal infectious diseaseDormant
BB
Indicative ·
70 / 100
View asset →
neutropeniaDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →